Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate

Journal of Rheumatology

Volumn 24, Issue 10, 1997, Pages 2035-2037

  Padeh, Shai ^a,b,d   Sharon, Nehama ^a   Schiby, Ginette ^a,c   Rechavi, Gideon ^a   Passwell, Justen H ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b Paediatric Department B   (Israel)

^c Pathology Department   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Juvenile rheumatoid arthritis; Lymphoma; Methotrexate

Indexed keywords

CD15 ANTIGEN; CD30 ANTIGEN; CHLORAMBUCIL; METHOTREXATE;

ARTICLE; CASE REPORT; CHILD; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL;

ANTIGENS, CD15; ANTIGENS, CD30; ARTHRITIS, JUVENILE RHEUMATOID; BIOPSY; CHILD; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; METHOTREXATE;

EID: 0030839371     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kremer J, Lee J: The safety and efficacy of low dose of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
2. Taillan B, Garnier G, Castanet J, Ferrari E, Pesce A, Dujardin P: Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate. Clin Rheumatol 1993;12:93-4.
3. Shiroky J, Frost A, Skelton J, Haegert D, Newkirk M, Neville C: Complication of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 1991;18:1172-15.
4. Kamel O, Rijn MVD, LeBrun D, Weiss L, Warnke R, Dorfman R: Lymphoid neoplasm in patients with rheumatoid arthritis and dermatomyositis. Hum Pathol 1994;25:638-42.
5. Kamel O, Rijn M, Weiss L, et al: Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
6. Shiroky J, Newkirk M: Reversible lymphomas (letter). N Engl J Med 1993;329:1657-8.
7. Kauppi MJ, Savolainen HA, Anttila VJ, Isomaki HA: Increased risk of leukemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Paediatr 1996;85:248-50.
8. Claviez A, Tiemann M, Peters J, Kreipe H, Schneppenheim R, Parwaresch R: The impact of EBV, proliferation rate, and Bcl-2 expression in Hodgkin's disease in childhood. Ann Hematol 1994;68:61-6.
9. Kingsmore S, Hall B, Allen N, Rice J, Caldwell D: Association of methotrexate, rheumatoid arthritis and lymphoma: Report of cases and literature review. J Rheumatol 1992;19:1462-5.
10. Salloum E, Cooper DL, Howe G, et al: Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943-9.
11. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB: Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991;18:809-14.
12. Seidel H, Moe PJ, Nygaard R, Nygaard K, Brede W. Borsi JD: Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr Hematol Oncol 1994;11:165-72.
13. Drappa J, Akshay K, Vaishnaw AK, Sullivan KE, Li Chu J, Elkon KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996;335:164-9.
14. Rieux-Laucat F, Le Deist F, Hivroz C, et al: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
15. Lindskov R, Wulf H, Wantzin G, Niebuhr E: Sister chromatid exchange in patients treated with methotrexate for psoriasis. J Invest Dermatol 1984;82:458-9.
16. Bailin P, Tindall JP, Roenigk HH Jr, Hogan MD: Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA 1975;232:359-62.